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Abstract
Background: Healthcare-associated (HCA) bloodstream infections (BSI) have been associated with worse outcomes,
in terms of higher frequencies of antibiotic-resistant microorganisms and inappropriate therapy than strict
community-acquired (CA) BSI. Recent changes in the epidemiology of community (CO)-BSI and treatment protocols
may have modified this association. The objective of this study was to analyse the etiology, therapy and outcomes
for CA and HCA BSI in our area.
Methods: A prospective multicentre cohort including all CO-BSI episodes in adult patients was performed over a
3-month period in 2006–2007. Outcome variables were mortality and inappropriate empirical therapy. Adjusted
analyses were performed by logistic regression.
Results: 341 episodes of CO-BSI were included in the study. Acquisition was HCA in 56% (192 episodes) of them.
Inappropriate empirical therapy was administered in 16.7% (57 episodes). All-cause mortality was 16.4% (56 patients)
at day 14 and 20% (71 patients) at day 30. After controlling for age, Charlson index, source, etiology, presentation
with severe sepsis or shock and inappropriate empirical treatment, acquisition type was not associated with an
increase in 14-day or 30-day mortality. Only an stratified analysis of 14th-day mortality for Gram negatives BSI
showed a statically significant difference (7% in CA vs 17% in HCA, p = 0,05). Factors independently related to
inadequate empirical treatment in the community were: catheter source, cancer, and previous antimicrobial use; no
association with HCA acquisition was found.
Conclusion: HCA acquisition in our cohort was not a predictor for either inappropriate empirical treatment or
increased mortality. These results might reflect recent changes in therapeutic protocols and epidemiological
changes in community pathogens. Further studies should focus on recognising CA BSI due to resistant organisms
facilitating an early and adequate treatment in patients with CA resistant BSI.
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Background
Bloodstream infections (BSI) remain a leading cause of
morbidity and mortality [1]. The early administration of
appropriate antibiotics, which has been shown to be an
independent protector for mortality in many analyses
[2,3], is crucial to improving the outcome for patients
with BSI. Epidemiological data are essential for designing
treatment protocols adapted to the local area that com-
prise coverage against the most prevalent organisms,
including those producing emerging antimicrobial re-
sistance mechanisms.
In the last decade, a new acquisition category, healthcare-
associated (HCA) infections, has been proposed as a
result of the development of ambulatory alternatives
to hospitalized healthcare [4-10]. Previous studies as-
sociated HCA BSI with an increased risk for drug-
resistant organisms, inappropriate empirical therapy,
and mortality, when compared to strict community-
acquired (CA) episodes [4,6,8,9,11]. However, since
these data were reported, various multidrug-resistant
(MDR) organisms have emerged as a cause of strict
community-acquired BSI (mainly extended-spectrum
beta-lactamase [ESBL]-producing enterobacteriaceae and
methicillin-resistant Staphylococcus aureus) [12,13]. Add-
itionally, in Spain, recommendations for empirical therapy
were changed in order to consider both HCA organisms
and multidrug-resistant community-borne organisms in
specific situations [12,14]. The increased awareness that
CO- BSI may be caused by specific antibiotic-resistant
organisms would have led to the reduced risk of these
patients receiving inappropriate therapy. In this context,
the objective of our study was to analyse the current
etiology, therapy and outcomes for strict community-
acquired (CA) and HCA bacteremia in our area.
Methods
The strengthening the reporting of observational studies in
epidemiology (STROBE) recommendations for reporting
observational studies [15] were followed in this report.
Study design and patient selection
This analysis is part of the SAEI/SAMPAC Bacteremia
project, aimed at investigating different aspects of BSI
and improving the management of patients with BSI in
Andalusia, Spain. The study involved a prospective co-
hort of all consecutive adult in-patients with clinically
significant BSI, in 15 public hospitals (10 tertiary and 5
community) in Andalusia, Spain, from October 1rst to
December 31th 2006 (to March 31th 2007 in community
centres). Patients were followed for 30 days. In this re-
port, we analysed 341 episodes of CO-BSI in the cohort
(192 [56%] classified as HCA, and the remainder as CA).
Patients with community-onset bacteremia not admitted
to hospital were not included in this study (those were 1
CA and 3 HCA episodes from the initial cohort). The
sample size was similar to that in previous studies
[4,8,9], which would provide a β error of 0.71 for a 10%
crude difference in mortality between HCA and CA epi-
sodes. The general epidemiological data for HCA and
CA episodes have been reported previously [10], being
the main significant differences that the CA presented
more often an urinary source of the BSI (31% vs 21%,
p = 0,04) and were more often caused by S. pneumoniae
(18% vs 6%, p = 0,001); the HCA BSIs were more often
developed by neutropenic patients (1% vs 7%, p = 0,02),
more often related to a previous antimicrobial use (18%
vs 32%, p = 0,003), the source was more often un-
known (15% vs 23%, p = 0,05) or secondary to a catheter
device (0% vs 12%, p < 0,001) and was more often caused
by P. aeruginosa (1% vs 9%, p = 0,01). As previously
reported, differences in mortality between HCA and CA
BSI were not statistically significant, either at day 14 (18%
vs 15%, p = 0.47) or at day 30 (21% vs 19%, p = 0.67) [10].
Susceptibility results were interpreted according to the
Clinical Laboratory Standards Institute (CLSI) recom-
mendations. ESBL production was confirmed by the
microdilution method if a 3 twofold dilution decrease in
the MIC of either ceftazidime or cefotaxime tested in
combination with clavulanic acid versus the MIC of each
agent when tested alone was observed [16].
The study was approved by the Ethics Committee of
the Hospital Universitario Virgen Macarena, which waived
the need to obtain informed consent.
Variables and definitions
The BSI was considered to be CO if the blood cultures
had been taken during the first 48 hours of hospital
admission, unless the infection was considered to have po-
tentially been acquired during a recent hospital admission
to an urgent care centre. The episodes were classified as
HCA, following Friedman et al. [4], when any of the fol-
lowing was present: intravenous therapy or specialist
nursing care at home in the 30 days before the BSI;
haemodialysis or intravenous chemotherapy in the 30 days
before the BSI; hospitalization for > 2 days in an emer-
gency care hospital in the 90 days before the BSI; or the
patient resided in a nursing home or long-term care facil-
ity. Episodes with none of the previous features were clas-
sified as CA.
Data were obtained from the charts and included:
demographics; ward of admission; presence of under-
lying chronic diseases and severity according to the
Charlson index [17]; invasive procedures; antimicrobial
use in the preceding 3 months; source of BSI using CDC
criteria [18];severity of the illness the day before the
onset of bacteremia (day −1) using the Pitt score [19];
severity of systemic inflammatory response syndrome
(SIRS at day 0, using predefined criteria [20]; etiology,
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and treatment adequacy. Empirical therapy was consid-
ered appropriate when an active antimicrobial agent
(according to susceptibility data) was administered at
recommended doses within the first 24 h after the blood
cultures had been performed, and inappropriate other-
wise. Pathogens were considered multidrug-resistant
according to Magiorakos et al’s criteria [21]. As outcome
variables, we used all-cause mortality at days 14 and 30,
and inappropriate empirical therapy.
Statistical analysis
Univariate analysis was performed using the chi-squared
or Fisher’s exact test, and the Student’s t-test or Mann–
Whitney U-test, for comparison of categorical and con-
tinuous variables, respectively. Crude association between
exposure to different variables and mortality or inadequate
treatment was estimated by calculating crude relative risk
(RR), with 95% confidence intervals (CI). Multivariate ana-
lyses were performed using logistic regression. Any
variable in the univariate analysis related to mortality
at a conservative significance level of < 0.2 was in-
cluded in the initial model. Variables were selected
using a backward stepwise process. Interactions be-
tween exposure to the variable of interest and other
variables were investigated. Since HCA acquisition
was our exposure variable of interest, it was retained
in the final models. The validity of the models was
evaluated using the Hosmer-Lemeshow test for esti-
mating goodness of fit to the data, and its discrimin-
ation ability by the area under the Receiver Operating
Characteristics (ROC) curve. All analyses were carried
out using the SPSS 15.0 software package (SPSS Inc.,
Chicago, IL, USA).
Results
Mortality predictors in community acquired BSI
The crude analysis for the association between exposure
to qualitative variables and 14- and 30-day mortality
rates is shown in Table 1. Neutropenia, ICU admission,
presentation with severe sepsis or shock, and BSI due to
Pseudomonas aeruginosa were associated with signifi-
cant increased 14- and 30-day mortality. A stratified ana-
lysis of mortality for Gram-positive and Gram-negative
BSI comparing HCA and CA BSI showed a statically
significant difference in 14th- day mortality among
Gram-negative BSI (7% in CA vs 17% in HCA, p = 0,05).
Respiratory tract infection as source of infection and
inappropriate empirical therapy were associated with
14-day mortality only. With respect to the quantita-
tive variables, age, Charlson index, and Pitt score
were significantly higher in patients who died, com-
pared to survivors at both day 14 (p values: 0.05, 0.002
and < 0.001, respectively) and 30 (p value: 0.05, 0.001, and
< 0.001, respectively).
A multivariate analysis of variables associated with 14-
day and 30-day mortality was performed next. Variables
introduced were: age, HCA acquisition, ICU admission,
type of hospital, Charlson index, neutropenia, Pitt score,
presentation with severe sepsis or shock, major sources
of infection, most frequent pathogens and inappropriate
empirical therapy. The interactions between empirical
therapy and source, aetiology and severity of SIRS
were also studied. HCA acquisition was not associ-
ated with an increased risk of death at days 14 or 30.
The final models are shown in Table 2. P values for
the Hosmer-Lemeshow goodness of fit test for models
obtained for 14- and 30-day mortality were 0.99 and
0.84, and the areas under the ROC curve were 0.86
and 0.82, respectively, showing a high predictive abil-
ity. Removing HCA-acquisition from the models did
not change predictive ability.
Antimicrobial resistance among community-acquired and
healthcare-related bloodstream infections aetiologies
A comparison of HCA and CA episodes for key anti-
microbial resistances of the most relevant BSI-causing
bacteria is shown in Table 3. Overall, resistance to
any of the antimicrobials considered, except multidrug-
resistance, was more frequent among isolates in HCA
episodes. Considering specific organisms, only penicillin-
resistance in S. pneumoniae was significantly more fre-
quent in HCA than in CA episodes. However, it must be
noted that there was a tendency for several organisms
which are naturally more resistant to certain antibiotics
(such as Enterobacter spp. or Pseudomonas aeruginosa) to
be more frequent in HCA.
Predictive factors of inadequate empiric treatment
We then analysed predictors for receiving inappropriate
empirical treatment. Table 4 shows the findings of the
univariate analysis for qualitative variables. ICU admis-
sion, cancer, ambulatory intravenous therapy, urinary cath-
eter, previous antimicrobial consumption, a BSI source
that was unknown, abdominal or catheter-related, BSI due
to P. aeruginosa, Enterobacter spp., Enterococcus spp, or
coagulase-negative staphylococci were all associated with
inappropriate empirical treatment. HCA-acquisition was
not associated with it. None of the quantitative variables
(age, Charlson index or Pitt score) showed a statistical
association. In the multivariate analysis, we found that
cancer, previous antimicrobial use, and vascular catheter-
related BSI were independent predictors of inappropri-
ate empirical therapy (Table 4). Again, HCA-acquisition
was not associated with inappropriate empirical therapy
(p = 0.5). For this model, the p value for the Hosmer-
Lemeshow goodness of fit test was 0.61, and the area
under the ROC curve was 0.63, showing moderate pre-
dictive ability.
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Differences between empirical therapy regimens used in
community-acquired and healthcare-related bloodstream
infections
We analysed whether there were significant differences
between empirical therapy regimens. Overall, the most
frequent antimicrobials used in HCA and CA episodes
were β-lactam/β-lactam inhibitors (28% vs 41%; p = 0.1),
carbapenems (21% vs 14%, p = 0.1), glycopeptides (19%
vs 8%, p = 0.003), third-generation cephalosporins (19%
vs 32%, p = 0.001), aminoglycosides in combination
(13% vs 11%, p = 0.6), and fluoroquinolones (10% vs 13%,
p = 0.3), respectively. With respect to the most frequent
sources of BSI, HCA episodes of intra-abdominal BSI were
less frequently treated with β-lactam/β-lactam inhibitors
than CA episodes (44% vs, 72%, p = 0.02) and more fre-
quently with carbapenems (28% vs 6%, p = 0.03); for the
combined catheter-related and unknown source episodes
(combined, because they both usually present as sepsis
with no apparent source), HCA episodes were more fre-
quently treated with glycopeptides (34% vs 9%, p = 0.001)
and less frequently with third-generation cephalosporins
(15% vs 50%); no differences were found for urinary
tract BSI.
Regarding the number of combined treatment with > 1
drug class among CA and HCA BSI there were no dif-
ferences between them (34,1% vs 34%, p = 0,99). The com-
bination of a cephalosporin plus levofloxacin was more
common among CA episodes (29% vs 21% in HCA
BSI, p = 0.32) and the combination of a cephalosporin
plus vancomycin was more common among HCA BSI
(14% among CA vs 23% in HCA, p = 0.49). These dif-
ferences were not significant.
Table 1 Univariate analysis of the association of exposure to qualitative variables and 14- and 30-day mortality
Variable No. dead at day 14 (%) RR(95% CI) P value No. dead at day 30 (%) RR (95% CI) P value
Gender Male 34 (17) Ref. - 42 (22) Ref. -
Female 22 (15) 0.9 (0.5–1.4) 0.56 27 (18) 0.9 (0.6–1.3) 0.4
Type of acquisition Community 22 (15) Ref - 29 (19) Ref. -
HCA 34 (18) 1.2 (0.7–2.0) 0.47 41 (21) 1.1 (0.7–1.7) 0.7
Type of hospital Tertiary 38 (15) Ref. - 51 (20) Ref. -
Community 18 (21) 1.4 (0.8–2.3) 0.2 19 (22) 1.1 (0.7–1.7) 0.7
Neutropenia No 49 (15) Ref. - 61 (19) Ref. -
Yes 7 (47) 3.1 (1.7–5.6) 0.001 9 (60) 3.2 (2.0–5.1) <0.001
ICU admission No 46 (14) Ref. - 61 (13) Ref. -
Yes 10 (45.5) 3.1 (1.9–5.4) <0.001 9 (41) 2.1 (1.2–3.7) 0.01
Severity of SISR Sepsis 19 (7.8) Ref. - 325 (13.1) Ref. -
Severe sepsis or shock 37 (38.5) 5.0 (3.0-8.3) <0.001 38/54 (39.6) 3.03 (2.0–4.5) <0.001
Source of bacteremia Vascular catheter 1 (4) Ref. - 2 (8) Ref. -
Urinary tract 7 (8) 1.9 (0.2–14.9) 0.5 9 (10) 1.3 (0.2–9.2) 1
Intraabdominal 12 (18) 4.1 (0.6–29.6) 0.1 17 (24) 2.9 (0.7–11.5) 0.1
Other source 9 (21) 4.9 (0.7–36.5) 0.1 10 (23) 2.7 (0.7–11.4) 0.2
Unknown 15 (23) 5.5 (0.8–39.7) 0.1 19 (29) 4.5 (0.9–30.1) 0.1
Respiratory tract 12 (25) 6.0 (0.8–43.5) 0.05 13 (27) 3.2 (0.8–13.2) 0.1
Etiology CONS 1 (4) Ref. - 2 (8) Ref. -
K. pneumoniae 2 (8) 2.0 (0.2–20.6) 1 4/(17) 2.0 (0.4-) 0.7
E. coli 13 (10.5) 2.5 (0.3–18.3) 0.5 17 (14) 1.7 (0.4–6.7) 0.7
S. aureus 7 (22) 5.2 (0.7–39.9) 0.1 8 (25) 3.0 (0.7-12.9) 0.2
S. pneumoniae 8 (22) 5.3 (0.7–39.9) 0.1 10 (28) 3.3 (0.8–13.9) 0.1
Enterococcus spp. 3 (23) 5.5 (0.7–48.0) 0.1 3 (23) 2.8 (0.5–14.5) 0.2
Enterobacter spp 2 (22) 5.3 (0.5–1.9) 0.2 3 (33) 4.0 (0.8–20.1) 0.1
P. aeruginosa 5 (36) 8.6 (1.1–66.1) 0.02 6 (43) 5.1 (1.2–22.1) 0.03
Empirical therapy Adequate 40 (14) Ref. - 53 (19) Ref. -
Inadequate 16 (28) 2.0 (1.2–3.3) 0.01 17 (30) 1.6 (1.0–2.5) 0.1
RR relative risk, CI confidence interval, Ref reference, HCA healthcare-associated, SIRS systemic inflammatory response syndrome, ICU intensive care unit,
CONS coagulase-negative staphylococci.
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In Table 5 we have described the aetiology, main
resistance and drug of the 57 episodes that received
inadequate empirical treatments (23 CA BSI and 34
HCA BSI). 24% were delayed treatments (5, 22% of
the inadequate CA BSI treatments and 9, 25% of the
inadequate HCA BSI treatments). The main regimes
of inadequate treatments were oxacilin resistant Gram-
positives treated with betalactams (3, 13% in the CA group
and 7, 205 of the inadequate HCA BSI treatments);
fluoroquinolones resistant Gram-negatives treated with
quinolones (2, 9% and 4, 12% in the inadequate CA and
HCA BI treatments respectively). Also 4 episodes due to
amoxicillin-clavulanic resistant E-coli were treated with
it in the CA BSI group and 2 ESBL producers Gram-
negatives were treated with ceftriaxone in the HCA
BSI subgroup.
Discussion
In the last decade, several studies have been published
stating the significance of HCA-acquisition to BSI out-
come [4-11]. In several of these, the mortality rate of
HCA BSI was significantly higher than that of strict
community BSI (15–30% vs 10–16%). Our data showed
that HCA acquisition was not independently associated
with increased mortality in BSI patients. Higher 14-day
mortality among HCA as compared to CA was only
found by Gram-negative BSI, even though there was no
difference in overall mortality of BSI, which may be in
part explained by a higher proportion of CNS among
HCA BSI.
There are other possible explanations for why we did
not find HCA-acquisition to be a risk factor for a worse
prognosis.
Firstly, the definition of an HCA BSI was not uniform
between the different studies. We used the criteria de-
veloped by Friedman et al. [4], which may be appropriate
for specialized ambulatory healthcare patterns and epi-
demiology in the US, but are perhaps less specific to
other areas of the world. For instance, in previous publi-
cations from the US, Staphylococcus aureus was a major
cause of bacteremia in HCA BSI groups [4,6,8], and was
related to frequent use of a permanent ambulatory ven-
ous catheter. However, the major cause of bacteraemia
in HCA episodes in our cohort was E. coli, as it was in a
previous Spanish study [9]. CO-BSI patients with minor
urinary tract procedures have been found to be at an
increased risk of ESBL-producing E. coli [12]. Using
Friedman’s criteria, which may be less sensitive for non-
catheter-related HCA BSI, many of those episodes might
not be considered as HCA. This means that there may
be important differences in epidemiology and outcome
of HCA BSI, depending on local epidemiology and
healthcare practices.
Secondly, the underlying mortality risk for patients
with CA episodes may vary between the studies. We
only included patients who required hospitalization,
while other studies included patients who were not hos-
pitalized [7] and where the risk of death ought, there-
fore, to be lower. It should be noted that in our study
the acute severity of underlying condition and the sever-
ity of SIRS at presentation was similar in patients with
HCA and CA BSI.
Thirdly, studies used different follow-up periods for
measuring mortality; Friedman et al. found higher mor-
tality in HCA-BSI at six months, but not during
hospitalization. A recent systematic review recommends
Table 2 Multivariate analysis of variables associated with mortality in patients with community-onset bloodstream
infections
β coefficient OR (95% CI) P value
Mortality at day 14
Healthcare-associated bacteremia 0.06 1.06 (0.52–2.14) 0.86
Charlson index 0.32 1.37 (1.16–1.63) <0.001
Presentation with severe sepsis or shock 1.74 5.70 (2.13–15.23) 0.001
Urinary tract source −1.85 0.15 (0.05–0.44) <0.001
Inappropriate empirical therapy 1.18 3.33 (1.42-7.69) 0.005
Mortality at day 30
Healthcare-associated bacteremia −1.75 0.83 (0.45–1.57) 0.57
Age 0.02 1.02 (1.00–1.04) 0.01
Charlson index 0.34 1.41 (1.22–1.63) <0.001
Pitt score≥ 2 0.16 1.18- (0.99–1.41) 0.06
Presentation with severe sepsis or shock 1.20 3.32 (1.35–8.14) 0.009
Urinary tract source −1.68 0.18 (0.07–0.45) <0.001
Inappropriate empirical therapy 0.69 2.00 (0.95-4.34) 0.07
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that mortality should be assessed at day 30 for BSI stud-
ies [2]. We also collected data at day 14 to provide infor-
mation about early mortality, which might be related
more to the direct effect of bacteremia [3].
And fourthly, controlling for confounding is critical to
outcome studies of BSI [2]. Only one previous study
performed a multivariate analysis to investigate the im-
pact of HCA-acquisition on mortality [8], although the
results were not controlled for source or appropriateness
of therapy.
As expected, we found that inappropriate empirical
treatment was an important predictive factor for a worse
outcome in our study. Contrary to the findings of some
earlier studies [6,9], we did not find that HCA episodes
were associated with a higher probability of receiving
inappropriate empirical therapy, which may further ex-
plain why HCA episodes were not associated with
increased mortality. When we compared our data
against those reported by McDonald et al. [6], who used
similar definitions, we found that inappropriate empir-
ical therapy was less frequently administered in HCA
episodes in our study (18% vs 25%). The fact that
carbapenems and glycopeptides were the second and
third antibiotic groups used in HCA episodes suggests
that physicians were aware of HCA-acquisition as a risk
factor for antibiotic-resistant organisms. On the other
hand, in our study, inappropriate empirical therapy was
more frequent in CA episodes (using Friedman’s criteria)
than in the study by McDonald et al. [6], which may re-
flect higher frequencies of antimicrobial resistance in
community isolates, at least in our area, and the need to
include other types of healthcare relation—such as urin-
ary tract procedures—or other invasive ambulatory pro-
cedures within the definition of an HCA episode. A
Table 3 Antimicrobial resistance among the most relevant aetiologies of community-onset bloodstream infections in
community-acquired and healthcare-related episodes
CA episodes HCA episodes P value
Escherichia coli N = 57 N = 71
Amoxicillin-clavulanic acid-resistant 9 (15.7) 9 (12.6) 0.61
Cefotaxime-resistant1 5 (8.7) 6 (8.4) 0.94
Ciprofloxacin-resistant 14 (24.5) 26 (36.6) 0.14
Gentamycin-resistant 2 (3.5) 5 (7.0) 0.46
Any resistance 15 (26.3) 25 (35.2) 0.33
Klebsiella spp. N = 12 N = 13
Amoxicillin-clavulanic acid-resistant 2 (16.6) 4 (30.7) 0.64
Cefotaxime-resistant1 1 (8.3) 1 (7.6) 1.0
Ciprofloxacin-resistant 0 1 (7.6) 1.0
Gentamycin-resistant 0 2 (15.3) 0.48
Any resistance 2 (16.6) 3 (23.0) 1.0
Pseudomonas aeruginosa N = 1 N = 13
Ceftazidime-resistant 0 1 (7.6) -
Imipenem-resistant 0 2 (15.3) -
Ciprofloxacin-resistant 0 2 (15.3) -
Amikacin-resistant 0 0 -
Streptococcus pneumoniae N = 27 N = 11
Penicillin-resistant 2 (7.4) 5 (45.4) 0.01
Erithromycin-resistant 2 (7.4) 1 (9.0) 0.56
Levofloxacin-resistant 0 1 (9.0) 0.28
Any resistance 2 (7.4) 5 (45.4) 0.01
Staphylococcus aureus N = 10 N = 22
Methicillin-resistant 0 6 (27.2) 0.14
All isolates N = 1592 N = 2032
Any resistance 32 (20.1) 71 (34.9) 0.001
Multi-drug resistance 10 (6.2) 22 (10.8) 0.18
CA strict community-acquired episodes, HCA healthcare-associated episodes.
1 all of them were ESBL producers. 2 10 and 11 episodes, respectively, were polymicrobials.
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Table 4 Univariate and multivariate analysis of factors related to inappropriate empirical treatment in
community-onset BSI
Variable Univariate analysis Multivariate analysis
Inappropriate empirical therapy RR (95% CI) P value OR RR (95% CI) P value
No. (%)
Gender Male 33/195 (17) Ref. - - - -
Female 24/144 (17) 1.0 (0.6–1.6) 0.95 - - -
Type of acquisition CA 23/149 (15) Ref. - - - -
HCA 34/190 (18) 1.2 (0.7–1.9) 0.5 - - -
Ambulatory IV therapy No 46/300 (15) Ref. - - - -
Yes 11/39 (28) 1.8 (1.1–3.2) 0.04 - - -
Type of hospital Tertiary 40/253 (16) Ref. - - - -
Community 17/86 (20) 1.25 (0.7–2.1) 0.4 - - -
Cancer No 38/260 (15) Ref. - 1,9 1,04-3,78 0,03
Yes 19/79 (24) 1.65 (1.0 –2.7) 0.05 - - -
Urinary catheter No 45/295 (15) Ref. - - - -
Yes 12/44 (27) 1.8 (1.1–3.1) 0.05 - - -
Central vascular Catheter No 48/304 (16) Ref. - 2,0 1,09-3,81 0,02
Yes 9/35 (26) 1.6 (0.9–3.0) 0.1 - - -
Previous antibiotics No 36/251 (14) Ref. - - - -
Yes 21/87 (24) 1.7 (1.1–2.7) 0.03 - - -
Previous surgery No 53/328 (16) Ref. - 2,0 1,04-3,78 0,03
Yes 4/11 (36) 2.25 (1.0–5.1) 0.08 - - -
Neutropenia No 53/324 (16) Ref. - - - -
Yes 4/15 (27) 1.6 (0.7– 3.9) 0.3 - - -
ICU admission No 50/317 (16) Ref. - - - -
Yes 7/22 (32) 2.0 (1.4–3.9) 0.05 - - -
Severity of SIRS Sepsis 45/244 (18) Ref. - - - -
Severe sepsis or shock 12/95 (13) 0.7 (0.4–1.2) 0.2 - - -
Source of BSI Urinary tract 8/87 (9) Ref. - - - -
Respiratory tract 7/48 (15) 1.6 (0.6–4.1) 0.3 - - -
Other source 6/40 (15) 1.6 (0.6–4.4) 0.3 - - -
Intraabdominal 15/71 (21) 2.3 (1.1–5.1) 0.03 - - -
Unknown 14/65 (21.5) 2.3 (1.1–5.2) 0.03 - - -
Catheter 7/24 (29) 3.2 (1.3–7.9) 0.01 - - -
Polymicrobial No 48/318 (15) Ref. −0.001 - - -
Yes 9/21 (43) 2.8 (1.6–5.0) - - -
Etiology S. pneumoniae 3/36 (8) Ref. - - - -
S. aureus 3/31 (10) 1.2 (0.2–5.3) 0.8 - - -
E. coli 13/123 (11) 1.3 (0.4–1.2) 0.7 - - -
K. pneumoniae 4/24 (16) 2.0 (0.5–8.1) 0.3 - - -
P. aeruginosa 4/14 (29) 3.4 (0.9–13.4) 0.06 - - -
CNS 9/24 (37) 4.5 (1.4–15.) 0.01 - - -
Enterococcus spp. 7/13 (54) 6.5 (2.0–21.3) <0.001 - - -
Enterobacter spp 6/9 (67) 8.0 (2.5–26.0) <0.001 - - -
Multi-drug- resistant bacteria No 50/307 (16) Ref. - - - -
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further problem relates to the fact that some MDR or-
ganisms are spread in the community and these might
have been the real cause of some strict community-
acquired BSI in our cohort. We observed that from the
57 HCA E. coli fluoroquinolones resistance was more
common than from CA E. coli episodes (37% vs 24%, p
= 0,14) and that methicillin resistance was more com-
mon in HCA than in CA S. aureus (27% vs 0%, p = 0,14)
but the difference was not significant may be due to
under power. By the contrary cefotaxime-resistant E. coli
Table 5 Inadequate empirical antimicrobial treatments regarding the acquisition and the aetiology
Community acquired (n = 23) Healthcare-related (n = 32)
Aetiology (main R) Empiric treatment Aetiology (main R) Empiric treatment
S. aureus CTX1 S. aureus (FqnR) CTX + LVX4
S. epidermidis(oxaR) CTX S. aureus (oxaR) AMX-CLV
S. epidermidis(oxaR) CTX S. epidermidis (oxaR) AMX-CLV
S. epidermidis(oxaR) AMX-CLV2 S. epidermidis (oxaR) AMX-CLV
S. pneumoniae Delayed S. epidermidis (oxaR) Delayed
Strep. viridans CIP3 S. epidermidis (oxaR) ERT5
Strep. viridans CIP S. epidermidis (oxaR) CIP
E. faecalis CTX S. epidermidis (oxaR) PIP-TAZ6 + AMK7
E. faecalis CIP + MET S. pneumoniae Delayed
E. faecalis Delayed S. pneumoniae Delayed
Rhodococcus equi CTX E. faecium (ampicilinR) ERT + AMK
E. coli (Amox-clav R) AMX-CLV E. faecalis CTX
E. coli (Fqn R) CIP E. faecalis CTX-AZT8
E. coli (Amox-clav R) AMX-CLV E. faecalis Delayed
E. coli (FQ R) CIP Corynebacterium spp. Delayed
E. coli Delayed E. coli (ESBL FqnR) CTX
E. coli Delayed E. coli (ESBL) CTX
E. coli (Amox-clav R) AMX-CLV E. coli (FQ R) CIP
E. coli (Amox-clav R) AMX-CLV E. coli Delayed
K. pneumoniae (Amox-clav R) AMX-CLV K. pneumoniae (ESBL) Delayed
Enterobacter spp. AMX-CLV K. pneumoniae VAN9
Citrobacter spp. AMX-CLV K. pneumoniae VAN
Bacteroides spp. Delayed Enterobacter spp. (cefotax FqnR) CTX + LVX
Enterobacter spp. CFZ10 + VAN
Enterobacter spp. Delayed
Enterobacter spp. (Pip-tazR) PIP-TAZ
Enterobacter spp. Delayed
P. aeruginosa (ceftazi R) CFZ
P. aeruginosa (ceftaz R) CFZ + VAN
P. aeruginosa (FQ R) CTX + LVX
P. aeruginosa (FQ R) CTX + LVX
Acrhomobacter spp VAN
Candida spp. AMX-CLV
1CTX cefotaxime, 2AMX-CLV amoxicillin-clavulanic, 3CIP ciprofloxacin, 4LVX levofloxacin, 5ERT ertapenem, 6PIP-TAZ piperacilin-tazobactam, 7AMK amikacin,
8AZT azytromicin, 9VAN vancomycin, 10CFZ ceftazidime.
Table 4 Univariate and multivariate analysis of factors related to inappropriate empirical treatment in
community-onset BSI (Continued)
Yes 7/32 (22) 1.3 (0.7–2.7) 0.4 - - -
RR relative risk, CI confidence interval, Ref reference, ICU intensive care unit, CNS coagulase-negative staphylococci.
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caused similar proportions of HCA and CA episodes
(9% vs 9%, p = 0,94). ESBL-producing E. coli has been
well recognized as a cause of community-onset BSI, as
explained above. Our results also confirm that commu-
nity isolates of MRSA were still anecdotal in our area by
the time the blood culture were collected [22].
Regarding the inadequate antimicrobial regimes in
Table 5 it is remarkable that 26% were considered inad-
equate due to a delayed treatment. Fluoroquinolones re-
sistant Gram-negatives treated with ciprofloxacine,
oxacilin resitant Gram-positives treated with betalactams
and 4 episodes of amoxicillin-clavulanic resistant E.coli
were the most important causes of inadequate treat-
ment. Although those resistances seem to be more
frecuent among HCA episodes it is remarkable the
present of amoxicillin-clavulanic resistant pathogens
among CA episodes. By the time this data was collected
this drug was a first line option in many urinary and
intrabdominal infections guidelines [23,24] as E.coli re-
sistance rate to amoxicillin-clavulanic was about 10-15%
as seem in several Spanish publications [25,26]. In the
last years this rate has increased up to 25%-30% so urin-
ary and intraabdominal guidelines have been modified.
The variables independently related with inappropriate
empirical treatment in community-onset BSI were: a
vascular catheter as a source of BSI; cancer; and previ-
ous antimicrobial use. All three variables are known risk
factors for certain types of pathogens or resistances that
are not typical for strict community pathogens, and they
should be taken into account when considering empir-
ical therapy.
Our study has some limitations. The number of in-
cluded cases is limited, although similar to previous
studies dealing with an outcome impact of HCA BSI.
For instance, as mentioned above, this fact limited the
analysis of individual microorganism resistance. The
findings would not be applicable to areas with a different
epidemiology of BSI or system of healthcare. Since the
study period was short, seasonal changes in the etiology
of BSI could not be considered. We did not include
non-hospitalized patients in our study, so that our find-
ings do not extend to BSI patients who were not
hospitalized.
Conclusions
HCA-acquisition was not a predictor for either inappro-
priate empirical treatment or increased mortality in our
community-onset cohort of BSI patients. These results
might reflect recent changes in therapeutic approaches
and epidemiological changes. Further studies should
focus on recognising CA BSI due to resistant organisms.
That may facilitate an early and adequate treatment in
patients with CA resistant BSI and therefore, a better
outcome.
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